Payment overview · 2025
General Payments
$2,154.02
119 reported records · 25 companies
Healthcare provider profile · identity verified
Timothy William Mcpherson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · STEELE, MO · NPI 1245264696
Verified facts
What the public records show
CMS Open Payments records show Timothy William Mcpherson, D.O. received $2,154.02 in general payments during 2025 across 119 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $278.54 | 12.9% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.37 | 9.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $167.77 | 7.8% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.19 | 7.7% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $164.43 | 7.6% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $155.77 | 7.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $152.07 | 7.1% | 8 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $111.72 | 5.2% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $104.61 | 4.9% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $103.20 | 4.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.44 | 3.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.53 | 2.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.00 | 2.5% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $49.66 | 2.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $47.55 | 2.2% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $46.04 | 2.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $35.69 | 1.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.04 | 1.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.44 | 1.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.30 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.26 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.66 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.74 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.76 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.24 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,133.80 | 118 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $307.84 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $278.54 | 15 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $164.43 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $136.29 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.68 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.68 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $116.31 | 9 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $111.72 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $104.61 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $103.20 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.10 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $84.44 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $72.00 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.53 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.00 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $49.66 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.88 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.88 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.88 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $47.55 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.31 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.04 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 278 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 340 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 124 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 181 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
340 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
50 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
181 | 35 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
75 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
86 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
124 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 4927 | 796 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1367 | 200 |
| Pregabalin | Pregabalin | 1263 | 222 |
| Gabapentin | Gabapentin | 838 | 277 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 821 | 139 |
| Alprazolam | Alprazolam | 536 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 536 | 96 |
| Furosemide | Furosemide | 460 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 101 |
| Lisinopril | Lisinopril | 409 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 408 | 59 |
| Metformin Hcl | Metformin Hcl | 371 | 76 |
| Omeprazole | Omeprazole | 367 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 68 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 346 | 141 |
| Farxiga | Dapagliflozin Propanediol | 340 | 54 |
| Carvedilol | Carvedilol | 335 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 308 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 301 | 80 |
| Tramadol Hcl | Tramadol Hcl | 298 | 75 |
| Potassium Chloride | Potassium Chloride | 295 | 58 |
| Montelukast Sodium | Montelukast Sodium | 290 | 49 |
| Eliquis | Apixaban | 278 | 35 |
| Ezetimibe | Ezetimibe | 273 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 251 | 99 |
| Celecoxib | Celecoxib | 246 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 245 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 218 | 117 |
| Zolpidem Tartrate | Zolpidem Tartrate | 212 | 43 |
| Losartan Potassium | Losartan Potassium | 207 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 181 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 21 |
| Sertraline Hcl | Sertraline Hcl | 169 | 23 |
| Mirtazapine | Mirtazapine | 159 | 20 |
| Ozempic | Semaglutide | 159 | 35 |
| Meloxicam | Meloxicam | 153 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 148 | 24 |
| Levetiracetam | Levetiracetam | 145 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 26 |
| Famotidine | Famotidine | 138 | 35 |
| Diazepam | Diazepam | 134 | 28 |
| Methocarbamol | Methocarbamol | 134 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 133 | 24 |
| Vascepa | Icosapent Ethyl | 132 | 19 |
| Donepezil Hcl | Donepezil Hcl | 130 | 19 |
| Myrbetriq | Mirabegron | 128 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 19 |
| Gemtesa | Vibegron | 124 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 35 |
| Valsartan | Valsartan | 114 | 28 |
| Trazodone Hcl | Trazodone Hcl | 113 | 22 |
| Ibuprofen | Ibuprofen | 111 | 28 |
| Ondansetron Odt | Ondansetron | 107 | 42 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 102 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 97 | 13 |
| Allopurinol | Allopurinol | 96 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 14 |
| Simvastatin | Simvastatin | 96 | 22 |
| Linzess | Linaclotide | 91 | 18 |
| Memantine Hcl | Memantine Hcl | 90 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 20 |
| Entresto | Sacubitril/Valsartan | 86 | 12 |
| Buspirone Hcl | Buspirone Hcl | 85 | 13 |
| Aripiprazole | Aripiprazole | 83 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 81 | 16 |
| Clonazepam | Clonazepam | 76 | 19 |
| Spironolactone | Spironolactone | 76 | 16 |
| Xarelto | Rivaroxaban | 75 | 11 |
| Jardiance | Empagliflozin | 74 | 19 |
| Baclofen | Baclofen | 73 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | suppressed |
| Topiramate | Topiramate | 69 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 13 |
| Trulicity | Dulaglutide | 65 | 12 |
| Prazosin Hcl | Prazosin Hcl | 63 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 62 | 14 |
| Naproxen | Naproxen | 61 | 24 |
| Fluconazole | Fluconazole | 60 | 20 |
| Torsemide | Torsemide | 60 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 56 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 56 | 16 |
| Roflumilast | Roflumilast | 55 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 19 |
| Rybelsus | Semaglutide | 51 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | 14 |
| Estradiol | Estradiol | 50 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 50 | 41 |
| Alcohol Pads | Alcohol Antiseptic Pads | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Movantik | Naloxegol Oxalate | 47 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 14 |
| Prednisone | Prednisone | 45 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 14 |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 11 |
| Azithromycin | Azithromycin | 36 | 30 |
| Nystatin | Nystatin | 36 | 19 |
| Promethazine Hcl | Promethazine Hcl | 36 | 16 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Minoxidil | Minoxidil | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Lubiprostone | Lubiprostone | 31 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 11 |
| Fentanyl | Fentanyl | 30 | suppressed |
| Kerendia | Finerenone | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 19 |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Nyamyc | Nystatin | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 18 |
| Atenolol | Atenolol | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 12 |
| Budesonide | Budesonide | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 20 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Febuxostat | Febuxostat | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Sirolimus | Sirolimus | 12 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 12 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,154.02 · 119 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, GEMTESA, JARDIANCE, JOURNAVX, Kerendia, LEQVIO, LYBALVI, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, Prolastin-C Liquid, QUTENZA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, Tymlos, VERQUVO, VOQUEZNA, Vest Therapy Und, YUPELRI, ZAVZPRET | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error